Display options
Cite
Fukase H, Fukuzaki K, Koja T, et al. Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys. Psychopharmacology (Berl). 1994;116(4):396-400doi: 10.1007/BF02247468.
Fukase, H., Fukuzaki, K., Koja, T., Nagata, R., & Lukas, S. E. (1994). Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys. Psychopharmacology, 116(4), 396-400. https://doi.org/10.1007/BF02247468
Fukase, H, et al. "Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys." Psychopharmacology vol. 116,4 (1994): 396-400. doi: https://doi.org/10.1007/BF02247468
Fukase H, Fukuzaki K, Koja T, Nagata R, Lukas SE. Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys. Psychopharmacology (Berl). 1994 Dec;116(4):396-400. doi: 10.1007/BF02247468. PMID: 7701039.
Copy Download .nbib Format: NLM
Share it on

Psychopharmacology (Berl). 1994 Dec;116(4):396-400. doi: 10.1007/BF02247468.

Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.

Psychopharmacology

H Fukase, K Fukuzaki, T Koja, R Nagata, S E Lukas

Affiliations

  1. Shin Nippon Biomedical Laboratories, Ltd. Kagoshima, Japan.

PMID: 7701039 DOI: 10.1007/BF02247468

Abstract

This study was conducted to characterize the opiate dependence potential of a number of opiate and non-opiate psychoactive drugs in morphine-dependent cynomolgus monkeys (Macaca fascicularis). In addition, the agonist/antagonist profiles of buprenorphine and butorphanol were directly compared. Six male cynomolgus monkeys were maintained on morphine (3.0 mg/kg, q.i.d.) for 6 months. On evaluation days, monkeys were scored for opiate withdrawal signs 18 h after the last dose of morphine. Single dose suppression studies were conducted by giving subcutaneous injections of morphine (3 or 6 mg/kg), naloxone (0.01, 0.05 or 0.1 mg/kg), buprenorphine (1, 3, 10, 30 or 100 micrograms/kg), butorphanol (0.01, 0.1, 1.0 or 3.2 mg/kg), haloperidol (0.01, 0.05 or 0.1 mg/kg), imipramine (2, 5 or 10 mg/kg) or saline and measuring the number and frequency of withdrawal signs that appeared over a 2-h period. In a separate precipitation experiment either saline or 0.01 or 0.1 mg/kg butorphanol was administered 2 h after the last maintenance dose of morphine. In the single dose suppression test, morphine completely suppressed most withdrawal signs while naloxone increased the severity of withdrawal. All doses of buprenorphine increased many withdrawal signs such as backward gait, rearing, chafing face, chain biting, vomiting, masturbation, and vocalizations after intimidation. Only a few signs were reduced, but the overall withdrawal scores were not significantly increased. Low doses of butorphanol suppressed some signs while the highest dose almost completely eliminated all withdrawal signs. Butorphanol also failed to precipitate opiate withdrawal, and actually reversed the signs present in the saline-treated monkeys. Imipramine and haloperidol had little effect on the morphine withdrawal syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)

References

  1. Eur J Pharmacol. 1981 Mar 26;70(3):293-300 - PubMed
  2. J Pharmacol Exp Ther. 1988 Aug;246(2):441-8 - PubMed
  3. Drug Alcohol Depend. 1985 May;15(1-2):15-8 - PubMed
  4. Neuropeptides. 1984 Dec;5(1-3):11-4 - PubMed
  5. NIDA Res Monogr. 1982 Apr;41:208-14 - PubMed
  6. Arch Gen Psychiatry. 1978 Apr;35(4):501-16 - PubMed
  7. Science. 1982 Sep 17;217(4565):1161-3 - PubMed
  8. Neuropeptides. 1984 Dec;5(1-3):15-8 - PubMed
  9. Eur J Pharmacol. 1991 Oct 22;203(3):387-91 - PubMed
  10. Eur J Pharmacol. 1986 Mar 11;122(1):143-7 - PubMed
  11. Drug Alcohol Depend. 1985 Feb;14(3-4):233-47 - PubMed
  12. Eur J Pharmacol. 1984 Apr 20;100(2):163-71 - PubMed
  13. Eur J Pharmacol. 1978 Aug 1;50(3):203-7 - PubMed
  14. Eur J Pharmacol. 1989 Nov 7;170(3):265-8 - PubMed

Substances

MeSH terms

Publication Types

Grant support